EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy

Pavel Novikov, Natalia Kozlovskaya, Sergey Moiseev, Eugene Shilov, Irina Bobkova, Adrian Schreiber, Dmitry Tsvetkov, Maik Gollasch, Nancy Mah, Khadija El Amrani, Andreas Kurtz

Biomedicine Hub · 2016

DOI: 10.1159/000453106 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomedicine Hub, 2016. Verfasst von Pavel Novikov und 10 weiteren Autor:innen. Beteiligte Einrichtung: I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of systemic autoimmune disorders characterized by necrotizing inflammation of medium-to-small vessels, a relative paucity of immune deposits, and an association with detectable circulating ANCAs. AAVs include granulomatosis with polyangiitis (renamed from Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Until recently, AAVs have not been viewed as complement-mediated disorders. However, recent findings predominantly from animal studies demonstrated a crucial role of the complement system in the pathogenesis of AAVs. Complement activation or defects in its regulation have been described in an increasing number of acquired or genetically driven forms of thrombotic microangiopathy. Coinciding with this expanding spectrum of complement-mediated diseases, the question arises as to which AAV patients might benefit from a complement-targeted therapy. Therapies directed against the complement system point to the necessity of a genetic workup of genes of complement components and regulators in patients with AAV. Genetic testing together with pluripotent stem cells and bioinformatics tools may broaden our approach to the treatment of patients with aggressive forms of AAV.

Schlagwörter

Stichwörter der Autor:innen

ANCA-associated vasculitisC5a receptorC5b-9CCX168ComplementGenetic testingHuman pluripotent stem cellsOpsonins

Autor:innen und Institutionen

  • I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Experimental and Clinical Research Center, a Joint Cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine at the Charité and the Max Delbrück Center for Molecular Medicine in…
  • Nephrology and Intensive Care Medicine, Campus Virchow, Berlin, Germany.
  • Koch Metchnikoff Forum, Section Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany.

Zitieren

APA

Novikov, P., Kozlovskaya, N., Moiseev, S., Shilov, E., Bobkova, I., Schreiber, A., Tsvetkov, D., Gollasch, M., Mah, N., El Amrani, K., & Kurtz, A. (2016). Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy. Biomedicine Hub. https://doi.org/10.1159/000453106

Vancouver

Novikov P, Kozlovskaya N, Moiseev S, Shilov E, Bobkova I, Schreiber A, et al. Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy. Biomedicine Hub. 2016. doi:10.1159/000453106

BibTeX
@article{Novikov2016,
  author = {Novikov, Pavel and Kozlovskaya, Natalia and Moiseev, Sergey and Shilov, Eugene and Bobkova, Irina and Schreiber, Adrian and Tsvetkov, Dmitry and Gollasch, Maik and Mah, Nancy and El Amrani, Khadija and Kurtz, Andreas},
  title = {Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy},
  journal = {Biomedicine Hub},
  year = {2016},
  doi = {10.1159/000453106}
}
Kostenlos starten →